Leo Pharma

Executive Summary

LEO Pharma is a Denmark-based global pharmaceutical company exclusively focused on medical dermatology, with a legacy spanning over a century. The company has built a robust portfolio of topical and biologic therapies for skin diseases such as psoriasis, atopic dermatitis, and actinic keratosis. Leveraging its expertise in drug development and strategic partnerships, LEO Pharma continues to invest in innovative treatments aimed at lifting the burden of disease for patients worldwide. The company's private status allows it to focus on long-term R&D without quarterly earnings pressure, positioning it strongly in the dermatology market.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on delgocitinib cream for chronic hand eczema85% success
• H2 2026Phase 3 top-line data for tralokinumab in atopic dermatitis pediatric population70% success
• Q4 2026Launch of new formulation for psoriasis topical treatment in Europe90% success